Nykode Therapeutics transfers to main market on Oslo Børs

Back

  • The sixth transfer on Oslo Børs in 2022
  • Market capitalisation of approximately NOK 8.2 billion

 

Oslo – 16 June 2022 – Oslo Børs, part of the Euronext Group, today congratulates Nykode Therapeutics (ticker: NYKD) on its transfer from Euronext Growth Oslo to the Oslo Børs main market, which now counts 211 companies. The company was listed on Euronext Growth Oslo in October 2020.

Nykode Therapeutics is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The company has developed a unique and innovative modular technology platform, targeting antigens to Antigen Presenting Cells, with the aim to treat and prevent cancer as well as infectious diseases.

At opening, the share price was set at NOK 28.28 per share based on its closing price on Euronext Growth Oslo on 15 June. This corresponds to a total estimated value of the company of approximately NOK 8.2 billion.

Michael Engsig, Chief Executive Officer of Nykode Therapeutics said: “Today, Nykode reached a significant inflection point, signaling our growth as a leading member of the biotech industry in Europe. Nykode’s uplisting to the main market of Oslo Børs enables us to reach a broader base of global institutional investors, increase liquidity of the Company’s shares, and better showcase our value proposition as a leading immunotherapy company with a unique and highly differentiated technology platform.

 

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.

The Company’s partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development. Nykode Therapeutics’ shares are traded on the Oslo Børs, the Norwegian Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at www.nykode.com.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €6.6 trillion in market capitalisation as of end March 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.